牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-07-02 AccNo: 0001213900-18-008565 Size: 34 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-06-19 AccNo: 0001213900-18-007853 Size: 33 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-06-11 AccNo: 0001213900-18-007467 Size: 36 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-06-11 AccNo: 0001213900-18-007467 Size: 36 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-06-01 AccNo: 0001213900-18-007100 Size: 98 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-04-25 AccNo: 0001213900-18-004912 Size: 51 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ EFFECT - Notice of Effectiveness Filed: 2018-04-04 AccNo: 9999999995-18-000748 Size: 1 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ POS AM - Post-Effective amendments for registration statement Filed: 2018-03-29 AccNo: 0001213900-18-003689 Size: 528 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Filed: 2018-03-28 AccNo: 0001213900-18-003554 Size: 7 MB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-03-23 AccNo: 0001213900-18-003345 Size: 168 KB 网页链接